 |
Top 32 CAR-T startups
Sep 30, 2025 | By Jason Kwon | 25 |
These startups develop CAR T-cell therapy - a form of immunotherapy that uses specially altered T cells — a part of the immune system — to fight cancer.
1
Country: USA | Funding: $172M
Wugen is developing off-the-shelf cellular therapies targeting solid tumors and hematologic malignancies
Wugen is developing off-the-shelf cellular therapies targeting solid tumors and hematologic malignancies
2
Country: USA | Funding: $1.3B
Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
3
Country: UK | Funding: $1.1B
Autolus utilises advanced cell programming CAR-T and manufacturing technologies and we have established a development-stage pipeline of products for the treatment of haematological malignancies and solid tumours.
Autolus utilises advanced cell programming CAR-T and manufacturing technologies and we have established a development-stage pipeline of products for the treatment of haematological malignancies and solid tumours.
4
Country: USA | Funding: $1B
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
5
Country: USA | Funding: $460.5M
Poseida Therapeutics utilizes best-in-class genome engineering capabilities to develop targeted lifesaving therapeutics.
Poseida Therapeutics utilizes best-in-class genome engineering capabilities to develop targeted lifesaving therapeutics.
6
Country: France | Funding: $393.5M
Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer.
Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer.
7
Country: USA | Funding: $369.5M
Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy.
Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy.
8
Country: USA | Funding: $363M
Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer.
Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer.
9
Country: USA | Funding: $340M
Capstan Therapeutics is advancing cell engineering to develop CAR-T therapeutics for a broad range of diseases.
Capstan Therapeutics is advancing cell engineering to develop CAR-T therapeutics for a broad range of diseases.
10
Country: USA | Funding: $337M
Ziopharm oncology is a biotechnology company that acquires, develops, and commercializes cancer therapies.
Ziopharm oncology is a biotechnology company that acquires, develops, and commercializes cancer therapies.
11
Country: Czech Republic | Funding: $316.9M
SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit.
SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit.
12
Country: USA | Funding: $256M
Acepodia is a therapeutics company that employs flexible therapeutic design to treat cancer.
Acepodia is a therapeutics company that employs flexible therapeutic design to treat cancer.
13
Country: Germany | Funding: $250M
GEMoaB develops universal CAR-T platform with focus on providing significantly safer and more efficacious treatments to patients who are suffering from hard-to-treat cancers and autoimmune diseases
GEMoaB develops universal CAR-T platform with focus on providing significantly safer and more efficacious treatments to patients who are suffering from hard-to-treat cancers and autoimmune diseases
15
Country: USA | Funding: $216M
Dispatch Bio was formed around the concept of solving two obstacles in cancer care: developing a treatment that can differentiate cancer cells from healthy cells while also addressing resistance mechanisms.
Dispatch Bio was formed around the concept of solving two obstacles in cancer care: developing a treatment that can differentiate cancer cells from healthy cells while also addressing resistance mechanisms.
16
Country: USA | Funding: $210M
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
17
Country: USA | Funding: $198M
Artiva Biotherapeutics is an oncology company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.
Artiva Biotherapeutics is an oncology company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.
18
Country: Germany | Funding: $197.4M
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.
19
Country: UK | Funding: $191.8M
Kuur Therapeutics is a cell therapy company working on new techniques to cure human diseases based upon a treatment method called cellular immunotherapy. This technique involves harnessing and enhancing the power of the human immune system to fight disease.
Kuur Therapeutics is a cell therapy company working on new techniques to cure human diseases based upon a treatment method called cellular immunotherapy. This technique involves harnessing and enhancing the power of the human immune system to fight disease.
20
Country: China | Funding: $190M
JW is focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer.
JW is focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer.
